[1] 李夏南,朱广迎. EGFR-TKI联合放疗治疗晚期非小细胞肺癌的研究进展[J].中国肺癌杂志,2014,17(4):357-362.[2] Chang CC,Chi KH,Kao SJ,et al.Upfront gefitinib/erlotinib treatmentfollowed by concomitant radiotherapy for advanced lung cancer:Amono-institutional experience[J].Lung Cancer,2011,73(2):189-194.[3] WangJ,Xia TY,Wang YJ,et al.Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer[J].Int J Radiat Oncol Biol Phys,2011,81(3):e59-65.[4] 支修益,石远凯,于金明.中国原发性肺癌诊疗规范(2015年版)[J].中华肿瘤杂志,2015,37(1):67-78.[5] Chen G,Feng J,Zhou C,et al.Quality of life (QoL) analyses from OPTIMAL (CTONG-0802),a phase Ⅲ,randomised,open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)[J].Ann Oncol,2013,24(6):1615-1622.[6] 中华医学会呼吸病学分会肺癌学组,中国肺癌防治联盟.晚期非小细胞肺癌分子靶向治疗专家共识(2013版)[J].中华结核与呼吸杂志,2014,37(3):177-183.[7] 庄梦琪.晚期非小细胞肺癌靶向药物治疗失败模式的临床分析[D].济南:山东大学,2014.[8] 张纬建,邹喜,洪金省,等.非小细胞肺癌诱导化疗后肿瘤体积变化规律及其影响因素[J].广东医学,2013,34(11):1741-1744.[9] 邹喜.非小细胞肺癌化疗后肿瘤体积变化规律及其影响因素研究[D].福州:福建医科大学,2012.[10] Mok TS,Wu YL,Thongprasert S,et al.Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J].N Engl J Med,2009,361(10):947-957.[11] Zhang L,Ma S,Song X,et al.Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer(INFORM:C-TONG0804):a multicentre,double-blind randomised phase 3 trial[J].Lancet Oncol,2012,13(5):466-475.[12] Zhou C,Wu YL,Chen G,et al.Erlotinib versus chemotherapy as first-line treatmenl for patients with advanced EGFR mutation-positive non-small-cell lung cancer(OPTIMAL,CTONG-0802):a multicentre,open-label,randomised,phase 3 study[J].Lancet Oncol,2011,12(8):735-742.[13] Mitsudomi T,Morita S,Yatabe Y,et al.Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405):an open label,randomised phase 3 trial[J].Lancet Oncol,2010,11(2):121-128.[14] Alexander BM,Othus M,Caglar HB,et al.Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy[J].Int J Radiat Oncol Biol Phys,2011,79(5):1381-1387.[15] Akamatsu H,Inoue A,Mitsudomi T,et al.Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer:combined analysis of two Phase Ⅲ trials (NEJ 002 and WJTOG 3405)[J].Jpn J Clin Oncol,2013,43(6):664-668. |